These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 18230551

  • 1. Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty.
    Metallidis S, Topsis D, Nikolaidis J, Alexiadou E, Lazaraki G, Grovaris L, Theodoridou A, Nikolaidis P.
    J Chemother; 2007 Dec; 19(6):682-7. PubMed ID: 18230551
    [Abstract] [Full Text] [Related]

  • 2. Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
    Landersdorfer CB, Kinzig M, Hennig FF, Bulitta JB, Holzgrabe U, Drusano GL, Sörgel F, Gusinde J.
    Antimicrob Agents Chemother; 2009 May; 53(5):2074-81. PubMed ID: 19223648
    [Abstract] [Full Text] [Related]

  • 3. Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
    Fukuda M, Yamada M, Kinoshita S, Inatomi T, Ohashi Y, Uno T, Shimazaki J, Satake Y, Maeda N, Hori Y, Nishida K, Kubota A, Nakazawa T, Shimomura Y.
    Adv Ther; 2012 Apr; 29(4):339-49. PubMed ID: 22529026
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
    Wagner RS, Abelson MB, Shapiro A, Torkildsen G.
    Arch Ophthalmol; 2005 Sep; 123(9):1282-3. PubMed ID: 16157821
    [No Abstract] [Full Text] [Related]

  • 5. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty.
    Malincarne L, Ghebregzabher M, Moretti MV, Egidi AM, Canovari B, Tavolieri G, Francisci D, Cerulli G, Baldelli F.
    J Antimicrob Chemother; 2006 May; 57(5):950-4. PubMed ID: 16551691
    [Abstract] [Full Text] [Related]

  • 6. Diffusion of levofloxacin into bone and synovial tissues.
    Rimmelé T, Boselli E, Breilh D, Djabarouti S, Bel JC, Guyot R, Saux MC, Allaouchiche B.
    J Antimicrob Chemother; 2004 Mar; 53(3):533-5. PubMed ID: 14963066
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
    Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL.
    Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980
    [Abstract] [Full Text] [Related]

  • 8. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED, Hovde LB, Sprandel KA, Rodvold KA, Rotschafer JC.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [Abstract] [Full Text] [Related]

  • 9. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery.
    Metallidis S, Charokopos N, Nikolaidis J, Alexiadou E, Lazaraki G, Koumentaki E, Tsona A, Theodoridis G, Nikolaidis P.
    Int J Antimicrob Agents; 2006 Nov; 28(5):428-32. PubMed ID: 17034992
    [Abstract] [Full Text] [Related]

  • 10. High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy.
    Murillo O, Pachón ME, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Gudiol F, Ariza J.
    J Infect; 2009 Mar; 58(3):220-6. PubMed ID: 19217166
    [Abstract] [Full Text] [Related]

  • 11. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy.
    Lai WW, Chu KO, Chan KP, Choy KW, Wang CC, Tsang CW, Pang CP.
    Am J Ophthalmol; 2007 Aug; 144(2):315-8. PubMed ID: 17659971
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I, Cars O.
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [Abstract] [Full Text] [Related]

  • 13. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.
    Capitano B, Mattoes HM, Shore E, O'Brien A, Braman S, Sutherland C, Nicolau DP.
    Chest; 2004 Mar; 125(3):965-73. PubMed ID: 15006955
    [Abstract] [Full Text] [Related]

  • 14. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone.
    Ozyuncu O, Nemutlu E, Katlan D, Kir S, Beksac MS.
    Int J Antimicrob Agents; 2010 Aug; 36(2):175-8. PubMed ID: 20418070
    [Abstract] [Full Text] [Related]

  • 15. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J, Hovde LB, Simonson D, Rotschafer JC.
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [Abstract] [Full Text] [Related]

  • 16. Penetration of newer quinolones in the empyema fluid.
    Liapakis IE, Kottakis I, Tzatzarakis MN, Tsatsakis AM, Pitiakoudis MS, Ypsilantis P, Light RW, Simopoulos CE, Bouros DE.
    Eur Respir J; 2004 Sep; 24(3):466-70. PubMed ID: 15358708
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA, Du X, Nicolau DP.
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.
    Kontou P, Manika K, Chatzika K, Papaioannou M, Sionidou M, Pitsiou G, Kioumis I.
    Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621
    [Abstract] [Full Text] [Related]

  • 19. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
    Yağci R, Oflu Y, Dinçel A, Kaya E, Yağci S, Bayar B, Duman S, Bozkurt A.
    Eye (Lond); 2007 Jul; 21(7):990-4. PubMed ID: 16732216
    [Abstract] [Full Text] [Related]

  • 20. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
    McCulley JP, Caudle D, Aronowicz JD, Shine WE.
    Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.